Positive HER3 could be a marker of poor response to neoadjuvant dual anti-HER2 therapy in breast cancer (CROSBI ID 733567)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Ramić, Snježana ; Perić Balja, Melita ; Veliki Dalić, Irena ; Milković Periša, Marija ; Orešic, Tomislav ; Milas, Ivan
engleski
Positive HER3 could be a marker of poor response to neoadjuvant dual anti-HER2 therapy in breast cancer
Breast cancer patients with over expressed human epidermal growth factor receptor 2 (HER2) recive dual anti-HER2 blockade with trastuzumab and pertuzumab in the neoadjuvant therapy. According to published literature, HER3 can mediate resistance to anti-HER2 therapy. The aim was to search for predictive factors of anti-HER2 neoadjuvant therapy. Poorer response to anti-HER2 therapy in HER3 positive breast cancer patients suggests a possibility for a new treatment option with directed anti-HER3 therapy.
Breast cancer, human epidermal growth factor receptor 2 (HER2) , neoadjuvant therapy, HER3
16th St. Gallen International Breast Cancer Conference
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
S77-S77.
2019.
nije evidentirano
objavljeno
10.1016/S0960-9776(19)30280-2
Podaci o matičnoj publikaciji
The Breast
0960-9776
1532-3080
Podaci o skupu
16th St.Gallen International Breast Cancer Conference
poster
20.03.2019-23.03.2019
Beč, Austrija
Povezanost rada
Temeljne medicinske znanosti